Results from a pilot study examining a shortened prednisone taper of 8 weeks’ length rather than 26 weeks suggest it may be possible to reduce patients duration of exposure to glucocorticoids.
Chee Kay Cheung, MBCHB, MRCP, PhD, discusses unmet needs in the management of IgAN, commenting on the need for new medication and highlighting budesonide and SGLT2 inhibitors.
Canadian researchers found that patients with immune-mediated inflammatory diseases (IMIDs) don't face a heightened risk of venous thromboembolism events after recovering from COVID-19 compared to those without IMIDs. However, certain comorbidities can influence this risk, emphasizing the importance of individualized patient care.
SARS-CoV-2 infection may elevate risk for certain autoimmune disorders, suggests study. Regular post-COVID monitoring needed to detect and manage potential autoimmune consequences.